Luminex's Q1 Revenues Rise 9 Percent on Jump in Royalties, Assay Sales | GenomeWeb

NEW YORK (GenomeWeb News) – Luminex reported after the close of the market Monday that its first-quarter 2013 revenues increased 9 percent, driven by a 23 percent increase in royalty revenues year over year and a jump in assay sales.

Austin, Texas-based Luminex brought in total revenues of $53.2 million for the three months ended March 31, compared to revenues of $48.7 million for the first quarter of 2012. It beat the consensus Wall Street estimate for revenues of $52 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.